SCHEDULE 13G/A: Rock Springs Capital Reduces Stake in Travere Therapeutics to 3.3%

Rock Springs Capital Management LP and its affiliates have filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 3.3% in Travere Therapeutics, Inc. common stock.

Summary

• Rock Springs Capital Management LP, Rock Springs Capital LLC, Rock Springs Capital Master Fund LP, Mark Bussard, and Kris Jenner (collectively, the 'Reporting Persons') have filed an Amendment No. 2 to Schedule 13G.
• The filing pertains to their beneficial ownership of Common Stock, par value $0.0001 per share, of Travere Therapeutics, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 2,921,196 shares of Travere Therapeutics, Inc. common stock.
• This aggregate amount represents 3.3% of the outstanding class of securities.
• The filing indicates shared voting and dispositive power over these shares, with no sole voting or dispositive power.
• The Schedule 13G is filed under Rule 13d-1(b), indicating the Reporting Persons are institutional investors (investment adviser, parent holding company, etc.) and hold the shares for passive investment purposes, not to change or influence control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the implied reduction in a significant institutional investor's stake, suggesting a potential decrease in confidence or portfolio reallocation, although the filing itself is a neutral disclosure of ownership.

Positives

• NA

Negatives

• The filing indicates a reduction in beneficial ownership from a previously higher stake (implied by 'Amendment No. 2' and the current 3.3% being below the typical 5% initial filing threshold for non-institutional investors), which could be interpreted as a decrease in conviction or a reallocation of capital by a significant institutional investor.

Risks

• NA

Future Outlook

This document is an ownership disclosure and does not contain any forward-looking statements or guidance regarding Travere Therapeutics, Inc.'s future outlook.

Management Comments

• Mark Bussard and Kris Jenner, as members of the management company, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under SEC rules.

Industry Context

This filing is a routine ownership disclosure by an institutional investor in the biotechnology/pharmaceutical sector. It reflects an investment firm's portfolio adjustments rather than broader industry trends or competitive dynamics.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: May interpret the reduction in institutional ownership as a signal of decreased institutional confidence, potentially influencing stock price perception.
• Company Management: May note the change in significant shareholder base, though the filing explicitly states the investment is passive.

Next Steps

• NA

Key Dates

Keywords

Travere Therapeutics, Rock Springs Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Biotechnology, Pharmaceuticals, Investment Management